A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer.

Author
Shin, Dong Bok · Kang, Shin Myung · Kyung, Sun Young · Park, Jeong-Woong · Jeong, Sung Hwan · Cho, Eun Kyung
Published online 2014-06-07
Journal Cancer chemotherapy and pharmacology
  See all Details

Abstract

Genexol-PM is a Cremorphor EL (CrEL)-free polymeric micelle formulation of paclitaxel that allows higher-dose administration with less hypersensitivity. This study was designed to evaluate the efficacy and safety of Genexol-PM and gemcitabine combination in advanced non-small cell lung cancer patients as a first-line treatment.

Reviews

Write Review

Saving... Saving... Cancel Save Cancel

Details

Title
A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer.
Author*
Shin, Dong Bok · Kang, Shin Myung · Kyung, Sun Young · Park, Jeong-Woong · Jeong, Sung Hwan · Cho, Eun Kyung
Published online
2014-06-07
Published
2014-08
Year
2014
Journal
Cancer chemotherapy and pharmacology
Type
Clinical Trial, Phase II · Research Article ·
Language
eng
PMID
24906423
Keywords
Adenocarcinoma · Drug Therapy · Antineoplastic Combined Chemotherapy Protocols · Therapeutic Use · Carcinoma, Non-Small-Cell Lung · Carcinoma, Squamous Cell · Lung Neoplasms · Patients · Lung · Cancer · Paclitaxel · Cells · Lung Cancer

Fields edited by Q-Sensei or Q-Sensei's users are marked with an asterisk (*).
This is Version 9 of this record. Anonymous user (IP:180.110.209.249) added this version on May 11, 2017. It is an edited version of the original data import from MEDLINE®/PubMed®. View changes to the previous version or view the complete version history.